---
{"dg-publish":true,"permalink":"/USMLE/Renal/Focal segmental glomerulosclerosis/"}
---

# Epidemiology
<span style="background:rgba(240, 200, 0, 0.2)">Most common cause of [[USMLE/Renal/Nephrotic syndrome\|nephrotic syndrome]] in adults, especially in African American and Hispanic populations</span>

---
# Etiology
- Heroin use
- [[USMLE/Infective disease/Human immunodeficiency virus\|HIV]] infection
- [[USMLE/Blood/Sickle cell disease\|Sickle cell disease]]
- Massive obesity
- [[USMLE/Biochemistry/Interferons and Tumor necrosis factor\|Interferon]] treatment
- Congenital malformations (e.g., Charcot-Marie-Tooth syndrome)

---
# Pathophysiology
Focal segmental glomerulosclerosis: <span style="background:rgba(240, 200, 0, 0.2)">sclerosis of glomeruli â†’ damage and loss of podocytes</span>

---
# Clinical features


---
# Diagnostics
- <span style="background:rgba(240, 200, 0, 0.2)">LM: segmental sclerosis and hyalinosis</span>![L9210.png](/img/user/appendix/L9210.png)
- <span style="background:rgba(240, 200, 0, 0.2)">EM: effacement of podocyte foot processes</span> (similar to [[USMLE/Renal/Minimal change disease\|minimal change disease]])

---
# Treatment
- Initial management: supportive therapy including an RAAS inhibitor (i.e., ACEI or ARB).
- Consider immunosuppressive therapy for all patients with [[USMLE/Renal/Nephrotic syndrome\|nephrotic syndrome]] due to FSGS.
	- Prednisone

---
